New Choline Deficiency Treatment Enters Clinical Trial
A new Phase 2b trial for IV Choline Chloride could provide a much-needed nutrient supplement for parenteral support patients.
Updated on Oct. 15, 2026 in Healthy Food
Live Poll
Should the FDA fast-track the approval of new medical treatments for rare, life-altering conditions?
Protara Therapeutics has finished enrolling 24 patients for the Phase 2b dose confirmation segment of the THRIVE-3 trial. This study evaluates IV Choline Chloride for adults across the United States who rely on long-term parenteral support.
Why it matters
Approximately 30,000 U.S. adults require long-term parenteral support, and about 80 percent of this population experiences choline deficiency. Currently, no parenteral formulations containing choline are approved, leaving a significant gap in treatment for these patients.
The Phase 2b trial is a dose-confirmation study of 24 patients, following a design intended to inform the larger 100-patient Phase 3 efficacy trial. Clinical outcomes for the participants remain unknown as the trial progresses through its data collection phase.
The players
Protara Therapeutics
A biopharmaceutical company headquartered in New York that focuses on developing therapies for patients with rare diseases.
The details
Choline is a critical substrate required for maintaining healthy liver function and supporting various physiological processes. Patients receiving long-term parenteral support frequently suffer from some degree of liver damage, potentially due to the absence of this nutrient. The trial investigates whether intravenous supplementation can address this deficiency in patients who cannot receive choline through oral intake.
Timeline
October 15, 2026: Protara Therapeutics announced the completion of enrollment for the Phase 2b study.
4Q 2026: The company expects to report interim results from the Phase 2b cohort.
Health Landscape
This research represents a departure from the current standard of care, which lacks an approved parenteral choline supplement. It follows the regulatory pattern established by FDA Orphan Drug and Fast Track designations to expedite treatments for patients with limited options.
Patients currently dependent on long-term parenteral support should discuss the risks of choline deficiency with their healthcare provider to monitor liver function. Decisions regarding participation in clinical trials or emerging treatment options are best reviewed with a primary care physician or specialist.
The takeaway
For patients on long-term parenteral support, monitoring liver health and nutritional status remains a critical priority. Consult with your medical team about the symptoms of nutrient deficiencies and stay informed about future clinical trial updates regarding essential substrate supplementation.
What happens next
Protara Therapeutics is scheduled to release interim trial results in the fourth quarter of 2026.
Further reading
Learn more about the latest developments in nutritional science in the Healthy Food section.
Live Poll
Should the FDA fast-track the approval of new medical treatments for rare, life-altering conditions?
